Satraplatin filing for prostate cancer to be withdrawn in EU
This article was originally published in Scrip
Executive Summary
GPC Biotech said that the EU marketing application for satraplatin for the treatment of prostate cancer is to be withdrawn by its partner for the drug in Europe, Celgene (previously Pharmion).